# PVRIG (CD112R)

Source: https://onco.cc/targets/pvrig/  
OnCo record `pvrig` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PVRIG is a brake on killer T cells and NK cells that reads CD112 on tumour cells, a cousin of the TIGIT pair. The antibody COM701 blocks it and is being tested in ovarian cancer.

## Summary

PVRIG (chromosome 7q22.1) is a cell-surface receptor for NECTIN2 (CD112) that may act as a co-inhibitory receptor suppressing T-cell receptor signals, inhibits T-cell proliferation after NECTIN2 binding and competes with CD226 for it; it is expressed at low levels on freshly isolated T and NK cells, predominantly memory and effector CD8 T cells and both CD16-positive and CD16-negative NK cells, and not on B cells, naive or helper T cells, monocytes or neutrophils (UniProt Q6DKI7). COM701 completed a phase 1/2 study with the TIGIT antibody BMS-986207 and nivolumab (NCT04570839) and is recruiting in relapsed platinum-sensitive ovarian cancer (NCT06888921).

## Fields

- Kind: Target
- Last checked: 2026-09-24
- Also known as: CD112R; PVR related immunoglobulin domain containing; C7orf15
- Tags: checkpoint-map
- Symbol: PVRIG
- Class: checkpoint
- Biology: An immunoglobulin-domain receptor with an ITIM-like tail; part of the CD226/TIGIT/CD96/PVRIG axis over CD155 and CD112.
- Where found: Memory and effector CD8 T cells and NK cells (UniProt Q6DKI7); Ovarian cancer trial of COM701 (NCT06888921)

## Notes

- Prevalence not recorded: HGNC and UniProt carry no positivity rates.

## Sources

- HGNC HGNC:32190: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:32190
- UniProt Q6DKI7: https://www.uniprot.org/uniprotkb/Q6DKI7/entry
- NCBI Gene 79037: https://www.ncbi.nlm.nih.gov/gene/79037
- ClinicalTrials.gov NCT06888921: https://clinicaltrials.gov/study/NCT06888921

## Connected records

- targets: [CD112 (nectin-2)](https://onco.cc/targets/nectin2/), [TIGIT](https://onco.cc/targets/tigit/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [TIGIT blockade](https://onco.cc/technologies/tigit-blockade/)
- pathways: [The cancer-immunity cycle](https://onco.cc/pathways/cancer-immunity-cycle/)
- terms: [Checkpoint (two meanings)](https://onco.cc/terms/checkpoint/)

---
JSON: https://onco.cc/api/v1/entities/pvrig.json